outcomes of patients with aggressive b-cell lymphoma after failure of anti-cd19 car t-cell therapy
Published 1 year ago • 272 plays • Length 48:12Download video MP4
Download video MP3
Similar videos
-
55:58
role of cd19 car t cells in second line large b cell lymphoma
-
47:52
gut microbiome correlates of response and toxicity following anti cd19 car t cell therapy
-
4:05
risk factors to predict post-cd19 car-t cell therapy outcomes in patients with lbcl
-
1:50
outcomes of patients with dlbcl following asct and/or car-t
-
1:39
out of specification anti-cd19 car t-cell products in aggressive b-cell lymphomas
-
5:36
investigating real-world outcomes of patients with r/r lbcl after cd19 car-t cell therapy
-
53:15
cd19 car t cells in lymphoid malignancies – 2018 update
-
40:20
high-risk mds follonig car t cells in patients with rr dlbcl
-
2:23
outcomes in progressive large b-cell lymphomas following cd19-specific car t cells
-
1:20
limitations of car t-cell therapy for dlbcl
-
3:20
outcomes for patients with disease progression following cd19-specific car t-cell therapy
-
40:15
cd19 targeted car t cells in refractory systemic lupus erythematosus
-
2:37
efficacy of bispecific cd19/cd22 car t-cells in b-cell malignancies
-
1:09
areas of unmet need for dlbcl: primary refractory disease and double-hit lymphoma
-
1:30:24
cellular therapy - a post ash 2020 summary
-
4:26
cd19-directed car-t in patients with r/r high-grade lymphoma
-
0:43
dr. martin on potential for car t-cell therapy in mcl landscape
-
1:33
second-line car-t therapy in b-cell lymphoma
-
2:10
new algorithm for second-line dlbcl: the role of car-t therapy